Verona Pharma plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Foreign exchange loss/(gain)
Amortization of debt issuance costs
Accretion of redemption premium on debt
Share-based compensation
Depreciation
Equity interest recognized as revenue
Changes in operating assets and liabilities:
Prepaid expenses
Tax incentive receivable
Other current assets
Right-of-use assets
Accounts payable
Accrued expenses
Operating lease liabilities
Income taxes
Other current liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of furniture and equipment
Purchases of short-term investments
Sale of short-term investments
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from issuance of ordinary shares
Payment of offering costs in connection with the issuance of ordinary shares
Proceeds from Term Loans
Payment of debt issuance costs
Repayment of Term Loans
SVB Term Loan repayment costs
Payments of withholding taxes from share-based awards
Proceeds from exercise of share options
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of the year
Cash and cash equivalents at end of the year
Supplemental disclosure of cash flow information:
Income taxes paid
Interest paid
Loss on extinguishment of debt
Fair value adjustment
Impairment of right-of-use asset
Proceeds from (Repayments of) Other Long-Term Debt
Accretion Expense
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in License Agreement Obligations
Proceeds From Revenue Interest Purchase And Sale Agreement ("RIPSA”)

Comments